My ePortfolio Register   

AACR 2017 /
Understanding response and resistance to cancer therapy: Lessons learned from melanoma

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.04.17
Views: 401
Rating:

Dr Jennifer Wargo - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Wargo speaks with ecancer at AACR 2017 about understanding the mechanisms of resistance in treating tumours, considering the influence of epigenetics, the tumour microenvironment and microbiota among others.

The influence of the microbiome on cancer risk and treatment response was reviewed in an ecancer article last year, and she describes how research in mouse models translates to human trials. 

Dr Wargo previously discussed the influence of the gut microflora on immunotherapy response at NCRI 2016.

She considers faecal transplant, which is proving effective in managing C. diff infections, as a route for treating cancers in the near future.

Dr Wargo goes on to discuss presentations from coworkers at the conference, including targeting stage III melanoma with BRAF inhibition before and after surgery.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence